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Abstract
Background: Polycomb Group (PcG) proteins are epigenetic silencers involved in maintaining cellular identity, and
their deregulation can result in cancer. Expression of Mel-18 and Bmi-1 has been studied in tumor tissue, but not
in adjacent non-cancerous breast epithelium. Our study compares the expression of the two genes in normal
breast epithelium of cancer patients and relates it to the level of expression in the corresponding tumors as well as
in breast epithelium of healthy women.
Methods: A total of 79 tumors, of which 71 malignant tumors of the breast, 6 fibroadenomas, and 2 DCIS were
studied and compared to the reduction mammoplastic specimens of 11 healthy women. In addition there was
available adjacent cancer free tissue for 23 of the malignant tumors. The tissue samples were stored in RNAlater,
RNA was isolated to create expression microarray profile. These two genes were then studied more closely first on
mRNA transcription level by microarrays (Agilent 44 K) and quantitative RT-PCR (TaqMan) and then on protein
expression level using immunohistochemistry.
Results: Bmi-1 mRNA is significantly up-regulated in adjacent normal breast tissue in breast cancer patients
compared to normal breast tissue from noncancerous patients. Conversely, mRNA transcription level of Mel-18 is
lower in normal breast from patients operated for breast cancer compared to breast tissue from mammoplasty.
When protein expression of these two genes was evaluated, we observed that most of the epithelial cells were
positive for Bmi-1 in both groups of tissue samples, although the expression intensity was stronger in normal tissue
from cancer patients compared to mammoplasty tissue samples. Protein expression of Mel-18 showed inversely
stronger intensity in tissue samples from mammoplasty compared to normal breast tissue from patients operated
for breast cancer.
Conclusion: Bmi-1 mRNA level is consistently increased and Mel-18 mRNA level is consistently decreased in
adjacent normal breast tissue of cancer patients as compared to normal breast tissue in women having had
reduction mammoplasties. Bmi-1/Mel-18 ratio can be potentially used as a tool for stratifying women at risk of
developing malignancy.
Background
Breast cancer is the leading cause of cancer mortality in
women [1]. The prognosis of breast cancer is dependent
on stage at the diagnosis, tumors diagnosed at early
stage having better prognosis. It is therefore important
to detect breast tumors at as early stage as possible
[2,3]. Benign diseases, like fibroadenomas, in the mam-
mary gland are associated with increased risk of breast
cancer in the same women, although in clinical practice
it is difficult to recognize women with fibroadenomas
who are at risk of developing breast cancer. There is a
need for diagnostic tools which may help stratifying the
risk for women with benign changes in their breasts.
Bmi-1 and Mel-18 may be genes used for this purpose
as our study will show.
There is increasing evidence that breast cancers arise
from deregulation of normal pathways in stem or early
progenitor cells due to mutations or epigenetic silencing
[4,5]. Polycomb Group (PcG) proteins are epigenetic
silencer genes involved in maintaining cellular identity,
and their deregulation can result in cancer [5].
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The deregulation of PcG genes may be one of the first
events in neoplasia of breast epithelium. Bmi-1 and
Mel-18 are two members of the PcG family. Bmi-1 has
been shown to maintain the stem cell pool by prevent-
ing premature senescence [6,7]. Bmi-1 expression has
been detected in normal mammary epithelium and
myoepithelial cells and later studies have implied Bmi-1
in connection with self-renewal of stem cells in breast
tissue [8]. Bmi-1 has been shown to be up-regulated in
breast tumors [7] as well as in several other tumor types
[7,9-12]. Over-expression induces lymphomas [11,13,14].
Bmi-1 has shown to regulate cellular senescence and
proliferation in rodent and human fibroblasts [15]. After
a finite number of cell division, most human cells
undergo cellular senescence, whereby cells irreversibly
cease to divide [16,17]. Bmi-1 can also bypass senes-
cence and immortalize human mammary epithelial cells
[18]. Bmi-1 has been studied in plasma of breast cancer
cells with healthy women as controls and results show
that levels of Bmi-1 expression may be a surrogate mar-
ker of poor prognosis [19]. This may be a very useful
noninvasive prognostic marker.
Mel-18 regulates cell proliferation and senescence via
transcriptional repression of Bmi-1 and c-myc oncopro-
teins [17], and is considered to play a dual role, being
either oncogenic in some tumor types or acting as a
tumor suppressor gene in others. In breast cancer, Mel-
18 is supposed to play a tumor suppressor role [20].
Mel-18 was originally cloned from B16 mouse mela-
noma cells and was shown to be highly expressed in
many tumor cells including human melanoma and
Hodgkin’s lymphomas [21,22].
It has been of our interest to investigate to what
extent normal breast tissue from breast cancer patients
is actually normal and to what it reflects cancer-specific
deregulation. Since both Mel-18 and Bmi-1 may play a
role in renewal of stem cells, deregulation of these pro-
teins may be one of the initial steps in development of
neoplasia and may be present even in non-cancerous tis-
sue adjacent to the tumor tissue. In the present study,
we wanted to analyze whether expression of these two
genes, both at the mRNA and protein level, differ
between normal tissue taken from breast cancer patients
compared to breast tissue from women who had no
actual or previous history of any kind of malignancy in
the breast.
Methods
Tissue Collection
Tissue samples from malignant tumors and normal
counterpart were obtained from patients operated for
breast cancer at Akershus University Hospital in the
period 2003-2009. In addition to the operated tumor, in
some cases large core needle biopsies were taken
preoperatively at the radiologist department either when
women came for screening or for diagnostic mammo-
graphy due to palpable mass. Both tumors and biopsies
were evaluated by a pathologist to confirm the diagnosis
and estimate the tumor cell content. All tumor samples
used in this study contained at least 60% tumor cells.
Tissue samples were immediately stabilized in RNAlater,
and then stored at -80°C. The women have signed a
written consent to participate in the study. The study
was approved by the Regional Committee for Medical
and Health Research Ethics (REK). A total numbers of
71 samples from tumors were analyzed. Mostly invasive
ductal carcinomas (64 samples) were included in the
study. The remaining were either lobular (5 samples) or
mixed (2 samples). Mean age at the operation was 60
years, median 60 years (range 34-83). 30 were classified
as lymph node positive and 41 as lymph node negative.
55 were estrogen positive and 43 samples were positive
for progesterone. Her-2 gene was found to be amplified
in 4 samples (only 21 of the samples were tested for
Her-2 gene amplification). Samples from 2 DCIS lesions
as well as samples from 6 fibroadenomas were also
included in the study. The clinical data are summarized
in tables 1 and 2.
Tissue samples from non cancer controls (reduction
mammoplasty) have been gathered since the autumn of
2008 and stabilized in the same way as the other sam-
ples. Mean age of these women was 39 years, median 36
years (range 20-68). Only two of these women were
postmenopausal. Our intension was to have a cohort of
healthy women to compare our results. These women
also signed a written consent and their names and iden-
tification number were registered in our databases.
RNA isolation
The surgical specimens and the large core needle biop-
sies were macroscopically dissected to obtain a sample
suitable for further processing. Frozen tissue was homo-
genized in Trizol (Invitrogen) with a 5 mm steal bead
(Qiagen) using a Mixer Mill MM301 (Retsch) at 30 Hz
for 2 min. RNA was isolated following the manufac-
turer’s protocol or the protocol of Wei and Kahn [23].
Purified RNA was dissolved in RNase-free water
(Ambion). Concentration was measured using Nano-
Drop and RNA quality assayed on an Agilent 2100
BioAnalyzer. The purified RNA was stored at -80°C.
Microarray Analysis and Statistical Analysis
500-1000 ng isolated RNA was converted to cDNA with
reverse transcriptase and an oligo(dT) primer bearing a
T7 promotor followed by in vitro transcription with T7
RNA polymerase to create amplified antisense RNA.
The amplified RNA was labeled with Cy3 or Cy5. As a
reference probe universal human reference RNA (UHR;
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Stratagene) was amplified and labeled as above. Amplifi-
cation and labeling efficiency was controlled using a
NanoDrop.
Labeled cRNA was hybridized to Agilent Whole
Human Genome Oligo Microarrays per the manufac-
turer’s protocol. After hybridization for 17 hours the
arrays were washed and scanned using an Agilent scan-
ner and microarray data extracted with Agilent Feature
Extraction software. Preprocessing of the microarray
data was done in J-Express Pro http://www.molmine.org
while between-array quantile normalization was done in
BioConductor [24]. The microarray data are submitted
to The ArrayExpress Archive http://www.ebi.ac.uk/
microarray-as/ae/ accession number E-MTAB-271.
Further statistical analysis was done in R. Between
group comparison were done using Student’s two-sided,
two-class t-test and ANOVA using the function aov.
Quantitative Real-time PCR (qPCR)
Total RNA was reverse transcribed using the High
Capacity RNA to-cDNA Master Mix (Applied Biosys-
tems) and cDNA was diluted with high molecular grade
water and stored at -20°C.
For qPCR, 25 ng cDNA, primer/probe sets and Taq-
Man Gene Expression Master Mix (2×) (Applied Biosys-
tems) were pipetted on a MicroAmp Optical 96-Well
Reaction Plate (Applied Biosystems) using the epMotion
5075 pipetting robot (Eppendorf). All samples were
pipetted in triplicates and a no template control was run
on each plate. The plate was run on the ABI PRISM
7900 HT Fast Real-Time PCR system (Applied Biosys-
tems) with the thermal profile: 50°C for 2 min, 95°C for
10 min and 50 cycles at 95°C for 15 seconds and 60°C
for 1 min. Analysis were done using ABI Prism SDS2.3
software and the RQ Manager 1.2 (Applied Biosystems).
As for the microarray studies the UHR RNA was used
as calibrator.
TaqMan® Gene Expression Assays from Applied Biosys-
tems (BMI1: Hs00180411_m1, PCGF2: Hs00810639_m1,
MRPL19: Hs00608519_m1, PPIA: Hs99999904_m1) were
used to perform qPCR. All gene assays target exon-exon
junctions to be mRNA specific. The final concentration of
the TaqMan gene expression assay used was 900 nM for
each primer and 250 nM for each probe.
Histology
The slides were evaluated by an experienced pathologist
(AJN) and graded according to the Nottingham grading
system (Nottingham modification of the Bloom-Richard-
son system) [25].
Immunohistochemistry
Immunohistochemistry was performed on 5 μm sections
from formalin-fixed, paraffin-embedded tissue applied to
coated slides. Deparaffinization, rehydration and epitope
retrieval were performed in a Dako PT link (Dako) at
97°C for 20 minutes. Dako Autostainer Plus together
with Envision™ Flex, high pH system (K8000, Dako)
were used in the immunostaining procedure following
the operating manual. The secondary antibody was incu-
bated for 20 minutes. Sections were stained with anti-
Bmi-1 (Santa Cruz Biotechnology) dilution 1:150 and
anti-Mel-18 (Santa Cruz Biotechnology) dilution 1:75.
Primary antibody incubated for 30 minutes. For Mel-18
visualization a FLEX + Rabbit (Linker) protocol was
used. The choice of antibodies was made primarily on
Table 1 Clinical data for the tumor patients
Histology
Ductal 64
Lobular 5
Mixed 2
Palpable
Yes 54
No 17
Grade
1 8
2 40
3 23
Lymph node status
N0 44
N1 19
N2 6
N3 2
Estrogen receptor status
ER+ 56
ER- 15
Progesterone receptor status
PR+ 41
PR- 30
HER2 receptor status
HER2+ 4
HER2- 17
Unknown 50
Recurrence/Metastasis 1
Death (not cancer specific) 2
Table 2 Age distribution for the patients within the
different groups
Cancers Non cancer controls DCIS Fibroadenomas
Mean Age 60 39 63 42
Median Age 60 36 63 45
Range 34-83 20-68 60-66 26-52
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the basis of literature studies, choosing clones used in
previous publications [20,26]. The slides were counter-
stained with Hagen’s Hematoxylin for visualization of
tissue structures.
Evaluation of immunohistochemistry
The amount of positive cells and immunoreactivity
intensity was evaluated semi- quantitative. For Bmi-1
only two grades were applied; if less than 10% of the
epithelial cells were immunoreactive to Bmi-1, the sam-
ple was recorded as negative for Bmi-1 immunoreactiv-
ity, while samples showing more than 10% of cells were
recorded as positive.
Soring grades for Mel-18 were as follows: Grade 1; < 5%
of the cells positive for Mel-18. Grade 2; 6% to 35% show-
ing positive immunoreactivity. Grade 3; 36-70% of the
cells showed positive immunoreactivity, and grade 4 when
more than 70% of the cells were positive for Mel-18
immunoreactivity. The intensity of the immunoreactivity
was also recorded, and the grading was as follows: Grade
1, weak intensitivity, grade 2; moderate intensitivity and
grade 3 when a strong intensitivity of the immunoreaction
was observed. The immunoreactivity for both Mel-18 and
Bmi-1 was evaluated by two independent investigators.
There was no discrepancy between the two investigators.
Results
Bmi-1 transcription level
When comparing the transcription level of Bmi-1 in the
different clinical groups, i.e. breast cancer, tissue taken in
the vicinity of the tumor, fibroadenomas and breast tissue
from non cancer controls, statistically significant differ-
ences were observed between the groups (table 3). Tran-
scription level in non cancer breast controls was lowest,
while transcription level in the normal adjacent tissue
was more similar to that of the tumor (Figure 1 and 2).
Of special interest was the difference in transcription
levels of Bmi-1 mRNA between non cancer controls and
normal tissue from cancer patients (p = 0.041).
Mel-18 transcription level
The relative transcription level of Mel-18 in breast tis-
sue from non cancer controls, fibroadenomas, tissue
taken in the vicinity of the tumor and the tumor itself,
is demonstrated in figure 3 and 4 and summarized in
table 3. The mRNA transcription level of Mel-18 was
statistically significantly higher in normal breast tissue
from non cancer controls compared to normal tissue
from cancer patients (p < 0.001).
There was a inverse relationship between the
transcription level of Mel-18 and Bmi-1
When we compared the transcription level of Bmi-1 and
Mel-18 in all categories (NC, non cancer controls, F,
fibroadenomas N, normal and T tumor) we observed an
inverse relationship between the transcription level of
the two genes (figure 5).
Quantitative Real-time PCR
To validate the results obtained by the microarray analy-
sis showing a clear inverse relationship between the
transcription levels of the two genes, transcription levels
of Bmi-1 and Mel-18 were also analyzed using qPCR.
Some of the samples could not be validated due to
insufficient mRNA amounts but all the groups were
represented (9 non cancer controls, 4 fibroadenomas, 2
DCIS, 22 normals from cancer patients, and 69 tumors).
Based on the work of McNeill et al [27] PPIA and
MRPL19 were included as endogenous controls. How-
ever, analysis of our results showed large variations in
transcription levels between the groups, especially for
PPIA (results not shown). As an alternative approach,
we therefore directly compared the transcriptional level
of Bmi-1 to that of Mel-18 (figure 6).
Results of immunohistochemistry
In our material all of the samples stained positive both
for Bmi-1 and Mel-18 but with different intensity.
When protein expression of Bmi-1 was evaluated using
immunohistochemsitry, as illustrated in figure 7 we
Table 3 Mean transcription levels of Bmi-1 and Mel-18 in
the different groups as well as the p-values and
confidence intervals for the group-wise comparisons
Bmi-1 Group mean SD p-value (confidence interval)
F N T
NC 0.098 0.184 <0.001
(-0.424
-0.149)
0.0418
(-0.346
-0.007)
<0.001
(-0.790
-0.419)
F 0.385 0.080 0.124
(-0.032
0.253)
<0.001
(-0.480
-0.157)
N 0.274 0.295 <0.001
(-0.620
-0.237)
T 0.703 0.659
Mel-18 Group mean SD p-value (confidence
interval)
F N T
NC 0.929 0.139 <0.001
(0.230
0.503)
<0.001
(0.362 0.707)
<0.001
(0.405
0.706)
F 0.563 0.115 0.065
(-0.0115
0.347)
0.021
(0.030
0.348)
N 0.395 0.352 0.827
(-0.172
0.214)
T 0.373 0.556
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observed that almost for every case the expression
intensity was stronger in normal tissue from breast can-
cer patients compared to normal breast tissue from non
cancer patients, indicating differences in amount of pro-
tein in the cells between these two groups.
When evaluating the protein expression of Mel-18
using immunohistochemistry, breast tissue from non
cancer individuals exhibited stronger expression inten-
sity compared to normal tissue from cancer patients for
almost every case, indicating probably higher amount of
Mel-18 protein in breast tissue from non cancer
controls.
However, both observations were subjectively made by
a pathologist and no statistical differences were seen in
numbers of positive cells between breast tissue from
non cancer controls compared to normal tissue taken
from a breast with a malignant tumor in the breast.
Discussion
In the present study we have analyzed levels of Mel-18
and Bmi-1 in normal breast tissue samples from patients
operated for cancer, and compared to breast tissue sam-
ples from patients operated for non malignant condition
and with no previously history of malignant disease.
We have shown that level of Bmi-1 is different in the
normal breast tissue from cancer patients compared to
normal breast tissue from non cancer controls at the
mRNA level and there is also differences in staining
intensity at the protein level, indicating that gene altera-
tions associated with tumor development is already
detected in the normal tissue, leading to higher risk for
development of a malignant disease in the breast. At the
same time we observed that at the protein level both
genes were expressed in all studied tissue types, with no
statistical differences in the numbers of positive cells
between breast tissue from non cancer controls com-
pared to normal tissue taken from a breast with a malig-
nant tumor in that same breast. This may suggest that it
is the change of expression above a certain threshold
that may matter in exerting a cancer phenotype.
As Bmi-1 and Mel-18 are involved in cell aging [6,17],
we looked for confounding effects of age of the patient
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Figure 1 Bmi-1 transcription levels for each sample and patient. Green = non cancer controls (NC), light blue = fibroadenomas (F), dark
blue = adjacent normal (N), and red = tumor (T). In cases where more than one tumor sample is shown for one patient, both preoperative and
peroperative tumor tissue were available. On the y-axis there is a logarithmic transcription level of our sample compared to a Universal Human
Reference (log2(expression of sample/expression of UHR)).
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Figure 2 Bmi-1 transcription levels for the clinical groups. Boxplot showing the transcription level of Bmi-1 within the clinical groups. Group
legends as in figure 1.
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Mel-18 transcription levels for each sample and patient
Figure 3 Mel-18 transcription levels for each sample and patient. Green = non cancer controls (NC), light blue = fibroadenomas (F), dark
blue = adjacent normal (N) and red = tumor (T). In cases where more than one tumor sample is shown for one patient, both preoperative and
peroperative tumor tissue were available. As in figure 1 there is logarithmic transcription level on the y-axis.
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even though cell aging and aging of a person is not the
same. Accounting for this we did regression analysis by
ANOVA and found that age is not a significant factor in
this respect (p = 0.47 for Bmi-1 and p = 0.61 for Mel-
18). The different clinical groups on the other hand,
were highly significant (p = 0.0013 for Bmi-1 and p =
0.013 for Mel-18).
The results from present study indicate that normal
breast tissue in cancer patients carries different charac-
teristics than that in women without previous history of
malignant disease. One may speculate that it is possible
to stratify women in risk groups for development of
malignant tumor in the breast, according to transcrip-
tion level ratios of genes like Bmi-1 and Mel -18.
After the introduction of mammography as a screening
method in most countries, breast tumors are more often
diagnosed at early stage. Most of the lesions detected by
mammography are benign, where benign histology is
confirmed by histological diagnosis of a biopsy. However,
new cancer cases known as “interval cancers” still emerge
and are diagnosed at later stage. The results from the
present study indicate that it may be possible to distin-
guish between patients at risk by analyzing the normal
breast tissue for genes like Bmi-1 and Mel-18.
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Figure 4 Mel-18 transcription levels for the clinical groups. Boxplot showing the transcription level of Mel-18 within the clinical groups.
Group legends as in figure 3.
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When comparing transcription level of mRNA for
Bmi-1 between different sources of tissue, we observed a
highly statistical difference in levels of transcription
level. In normal tissue from breast cancer patients Bmi-
1 mRNA was up-regulated, compared to tissue from
breast without history of malignant disease. Again, there
was no correlation between mRNA transcription level
and the amount of cells positive for Bmi-1 in different
groups, although intensitivity of immunoreactions were
different between different groups and followed the
same pattern as mRNA transcriptional level, indicating
that there may be “more” protein in cells where mRNA
transcriptional level was found to be high.
However, as in the case of Mel-18, mRNA transcrip-
tion level is of transcripts isolated from all cells from
which total RNA was isolated together and cannot
directly correlate to the number of positive cells stained
by immunohistochemistry. The number of cells in both
specimens (for mRNA and protein analysis) is unknown
and cannot be equal. Nevertheless the intensity of the
immunohistochemistry, indicating amount of protein
per cell, was inversely to what was observed for Mel-18
being higher in almost all samples from breast cancer
patients compared to controls. Bmi-1 expression is
necessary for normal cell cycle dynamics. It is possible
that there may be “threshold” of Bmi-1 protein expres-
sion, and when this “threshold” is overridden, this pro-
tein may start to function as an oncogene. The highest
transcription level of Bmi-1 was observed in invasive
tumor tissue. Expression of Mel-18 was also analyzed.
When transcription level of Mel-18 was analyzed in nor-
mal tissue from breast cancer patients, tumor tissue and
tissue from patients without malignant disease, the low-
est transcription level was observed in tumor tissue, and
the highest in tissue from benign breast tissue. If this
correlation reflects a direct functional interaction
between Bmi-1 and Mel-18 is not possible to evaluate in
this study. Nevertheless, we believe that expression ana-
lyses of both proteins may be an important tool for stra-
tifying patients at risk for development of malignant
disease in the breast. This is before the onset of an
eventual malignant disease and as Silva et al suggest
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Figure 5 Median transcription levels between the clinical groups. Comparison of the median transcription level of Bmi-1 and Mel-18 for
each clinical group shows an inverse correlation of the transcription level.
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[19] it can further be used as a diagnostic marker in
patients who have already been diagnosed with breast
cancer.
Data comprehensively comparing gene expression
between histologically normal breast epithelium of
breast cancer patients and cancer-free controls is lim-
ited. Similarly as our study Tripathi et al [28] did global
gene expression of these two groups and conclude that
cancer-related pathways are already perturbed in normal
epithelium of breast cancer patients. This is cohesive to
our study. Chen et al [29] also had the intention of
studying malignancy-risk gene signature in histologi-
cally-normal breast tissue, but they compared the tumor
tissue to the histologically normal tissue adjacent to the
tumor, which is also part of what has been done in our
study.
Saeki et al [30] reported a similar study on Bmi-1
where they found transcription level of the gene to be
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Figure 6 Quantitative real-time PCR shows the same inverse relationship between the transcriptional levels of Bmi-1 and Mel-18 as
the microarray data. The qPCR results were calculated using the comparative CT-method (-ΔΔCT) while the microarray results are given as the
difference in expression of the two genes (log2(expression of Bmi-1/expression of Mel-18)).
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ten times higher in cancer tissue than non cancer con-
trols. This is in coherence with our results except for
the magnitude. A reason for this may be the observed
large variation in tumor Bmi-1 levels in both materials
and tumor heterogeneity may be responsible for the
observed differences. By using laser micro dissection
one could more accurately see the exact tissue from
which mRNA was extracted.
Conclusion
In summary; we have in the present study demonstrated
for first time that the levels of Mel-18 and Bmi-1 is dif-
ferent in normal tissue from breast cancer patients com-
pared to breast tissue from non cancer controls. The
transcription level of Bmi-1 and Mel-18 in all clinical
categories (non cancer controls, fibroadenomas, normal,
and tumor) was inversely correlated. Mel- 18 and Bmi-1
are two essential proteins in stem cell renewal pathways.
Results from the present study indicate that expression
profile analyses of that Mel-18 and Bmi-1 may be a tool
for stratifying women at risk for development of malig-
nant disease.
List of abbreviations
PcG: Polycomb Group of Proteins; DCIS: Ductal Carci-
noma in Situ; UHR: Universal Human Reference; RP:
Reduction Mammoplasty; F: Fibroadenoma; N: Normal;
T: Tumor; and qPCR: Quantitative Real-time PCR;
Acknowledgements
We thank our surgical colleagues, Dr. S. Trønnes, Dr. B. Gravdehaug, and
Dr. E. Kjæstad at the Surgical Department, Akershus University Hospital and
colleagues at the Radiology Department same hospital for helping us collect
the samples from cancer patients. Likewise we would like to thank
colleagues at the Collosseum Clinic, Oslo, for providing samples from
mammoplasties. We are grateful to T. Sonerud, Department for Clinical
Molecular Biology (EpiGen), for help with performing the qPCR experiments.
Figure 7 Immunostaining. Normal tissue from non cancer controls (upper panel) and normal tissue adjacent to a tumor (lower panel) of Bmi-1
(left) and Mel-18 (right). Demonstrating the increase in staining of Bmi-1 in tumor tissue, and the decrease in staining of Mel-18 in the same
tissue. These are the outer limits and the staining of the groups in between are described in the text.
Riis et al. BMC Cancer 2010, 10:686
http://www.biomedcentral.com/1471-2407/10/686
Page 10 of 11
MR is a fellow of the Faculty of Medicine, University of Oslo, this work was
supported by grant number 2789119 from Helse Sør-Øst and internal grants
from Akershus University Hospital, grant number 2689023.
Author details
1Department of Surgery, Akershus University Hospital, Lørenskog, Norway.
2Department of Clinical Molecular Biology (EpiGen), Institute of Clinical
Medicine, Akershus University Hospital, University of Oslo, Lørenskog,
Norway. 3Department of Pathology, Akershus University Hospital, Lørenskog,
Norway. 4Institute of Clinical Medicine, University of Oslo, Lørenskog,
Norway.
Authors’ contributions
MR was involved in the design of the study, collected the clinical data,
contributed to the tissue collection and immunohistochemical analysis and
is responsible for the preparation of the manuscript. TL performed the
microarray experiments, contributed to the microarray, qPCR and statistical
analysis, and is responsible for the preparation of the figures and the final
formatting of the manuscript. AJN performed the immunohistochemical
analysis. HV contributed to the microarray analysis. VK and IB designed the
study, contributed to the preparation of the manuscript and supervised the
work of MR, TL and HV. All authors have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 July 2010 Accepted: 16 December 2010
Published: 16 December 2010
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74-108.
2. Paajanen H, Kyhala L, Varjo R, Rantala S: Effect of screening
mammography on the surgery of breast cancer in Finland: a population-
based analysis during the years 1985-2004. Am Surg 2006, 72:167-171.
3. Weigel S, Batzler WU, Decker T, Hense HW, Heindel W: First
epidemiological analysis of breast cancer incidence and tumor
characteristics after implementation of population-based digital
mammography screening. Rofo 2009, 181:1144-1150.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and
cancer stem cells. Nature 2001, 414:105-111.
5. Sparmann A, van LM: Polycomb silencers control cell fate, development
and cancer. Nat Rev Cancer 2006, 6:846-856.
6. Park , Morrison , Clarke : Bmi1, stem cells, and senescence regulation. J
Clin Invest 2004, 113:175-179.
7. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS,
Kim JW: Overexpression of Bmi-1 oncoprotein correlates with axillary
lymph node metastases in invasive ductal breast cancer. Breast 2004,
13:383-388.
8. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P,
Wicha MS: Hedgehog signaling and Bmi-1 regulate self-renewal of
normal and malignant human mammary stem cells. Cancer Res 2006,
66:6063-6071.
9. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP,
Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group
proteins is associated with cycling cells and degree of malignancy in B-
cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901.
10. Lindstrom MS, Klangby U, Wiman KG: p14ARF homozygous deletion or
MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Oncogene 2001, 20:2171-2177.
11. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL,
van LM, Colomer D, Campo E: BMI-1 gene amplification and
overexpression in hematological malignancies occur mainly in mantle
cell lymphomas. Cancer Res 2001, 61:2409-2412.
12. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM,
van LM, Betticher DC: The bmi-1 oncoprotein is differentially expressed
in non-small cell lung cancer and correlates with INK4A-ARF locus
expression. Br J Cancer 2001, 84:1372-1376.
13. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP,
Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group
proteins is associated with cycling cells and degree of malignancy in B-
cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901.
14. Alkema MJ, Jacobs H, van Lohuizen M, Berns A: Perturbation of B and T
cell development and predisposition to lymphomagenesis in eu-Bmi1
transgenic mice require the Bmi1 RING finger. Oncogene 1997,
15:899-910.
15. Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ, van LM,
Band V, Campisi J, Dimri GP: Control of the replicative life span of human
fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003,
23:389-401.
16. Dimri GP: What has senescence got to do with cancer? Cancer Cell 2005,
7:505-512.
17. Guo WJ, Datta S, Band V, Dimri GP: Mel-18, a polycomb group protein,
regulates cell proliferation and senescence via transcriptional repression
of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007, 18:536-546.
18. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, van LM, Campisi J,
Wazer DE, Band V: The Bmi-1 oncogene induces telomerase activity and
immortalizes human mammary epithelial cells. Cancer Res 2002,
62:4736-4745.
19. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, Lorenzo Y, Hurtado A,
Sanchez A, Bonilla F: Circulating Bmi-1 mRNA as a possible prognostic factor
for advanced breast cancer patients. Breast Cancer Res 2007, 9:R55.
20. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V, Dimri GP: Mel-18
acts as a tumor suppressor by repressing Bmi-1 expression and down-
regulating Akt activity in breast cancer cells. Cancer Res 2007,
67:5083-5089.
21. Tagawa M, Sakamoto T, Shigemoto K, Matsubara H, Tamura Y, Ito T,
Nakamura I, Okitsu A, Imai K, Taniguchi M: Expression of novel DNA-
binding protein with zinc finger structure in various tumor cells. J Biol
Chem 1990, 265:20021-20026.
22. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, Kluin-
Nelemans HC, Meijer CJ, Raaphorst FM: Unique polycomb gene
expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-
derived cell lines. Am J Pathol 2004, 164:873-881.
23. Wei J, Kahn J: Purification of Total RNA from Mammalian Cells and
Tissues. In DNA Microarrays: A Molecular Cloning Manual. Edited by: Bowtell
D, Sambrook J. Cold Spring Harbor, New York: Cold Spring Harbor
Laboratory Press; 2002:110-119.
24. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, et al: Bioconductor: open software development
for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
25. Bloom HJ, Richardson WW: Histological grading and prognosis in breast
cancer; a study of 1409 cases of which 359 have been followed for 15
years. Br J Cancer 1957, 11:359-377.
26. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL,
Li MZ, Xia YF, et al: Bmi-1 is a novel molecular marker of nasopharyngeal
carcinoma progression and immortalizes primary human
nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232.
27. McNeill RE, Miller N, Kerin MJ: Evaluation and validation of candidate
endogenous control genes for real-time quantitative PCR studies of
breast cancer. BMC Mol Biol 2007, 8:107.
28. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA,
Hirsch EF, Kavanah M, Mendez J, Stone M, et al: Gene expression
abnormalities in histologically normal breast epithelium of breast cancer
patients. Int J Cancer 2008, 122:1557-1566.
29. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T,
Agrawal D, McCarthy SM, Gruidl M, et al: Proliferative genes dominate
malignancy-risk gene signature in histologically-normal breast tissue.
Breast Cancer Res Treat 2010, 119:335-346.
30. Saeki M, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Diagnostic
importance of overexpression of Bmi-1 mRNA in early breast cancers. Int
J Oncol 2009, 35:511-515.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/686/prepub
doi:10.1186/1471-2407-10-686
Cite this article as: Riis et al.: Expression of BMI-1 and Mel-18 in breast
tissue - a diagnostic marker in patients with breast cancer. BMC Cancer
2010 10:686.
Riis et al. BMC Cancer 2010, 10:686
http://www.biomedcentral.com/1471-2407/10/686
Page 11 of 11
